The World Health Organization (WHO) has approved the first mpox vaccine for children aged one and above, marking a significant milestone in global public health efforts to combat the virus. The decision grants an Emergency Use Listing (EUL) for the Lc16m8 vaccine, developed by Japanese pharmaceutical company KM Biologics.
A Crucial Step in Controlling Mpox Outbreaks
The WHO announced its decision on Tuesday, stating that the EUL would facilitate greater and more timely access to vaccines in communities experiencing mpox outbreaks. “This approval is expected to enhance vaccine availability in outbreak settings,” the agency said.Administered as a single-dose vaccine, Lc16m8 is recommended for individuals aged one and older. This follows the WHO's prior approval of a vaccine manufactured by Danish company Bavarian Nordic, which was initially authorized for adults and later expanded to include individuals aged 12 and above.Rising Cases Among Children in the DRC
The need for expanded vaccine coverage is particularly urgent in regions like the Democratic Republic of Congo (DRC), where Save the Children reported a staggering 130% increase in mpox cases among children. Africa has borne the brunt of the outbreak, with over 53,000 cases and 1,100 deaths reported across 19 countries in 2024, according to the Africa Centers for Disease Control and Prevention (Africa CDC).Understanding Mpox
Mpox, formerly known as monkeypox, is a viral infection characterized by fever, fatigue, and painful rashes. The virus spreads through close skin-to-skin contact or contaminated materials such as bedding and clothing.Since the WHO declared mpox a global health emergency in August 2024, the virus has been reported in over 80 countries, necessitating urgent interventions.Japan’s Contribution to the Fight Against Mpox
Japan has pledged 3.05 million doses of the Lc16m8 vaccine to the DRC, accompanied by specialized syringes. This donation underscores the global commitment to combating the virus, particularly in vulnerable populations.Dr. Yukiko Nakatani, WHO’s Assistant Director-General for Access to Medicines and Health Products, described the approval as “a critical step in our response to the current emergency.” She emphasized the vaccine’s role as part of a comprehensive response strategy, including testing, diagnostics, treatment, infection prevention, and community engagement.A Comprehensive Approach to Pandemic Preparedness
The WHO continues to stress the importance of combining vaccination with other measures to control mpox outbreaks. The integration of the Lc16m8 vaccine into global health strategies highlights the potential for collaborative efforts to protect populations, especially children, from this viral threat.As the world grapples with mpox and other emerging diseases, this milestone serves as a reminder of the power of international cooperation in advancing public health. 
